



New Treatments... can't happen without you

Can an anti-cancer drug be used to treat people with early symptoms of Alzheimer's disease? Help us find out. Consider joining our MCLENA-1 study.

Purpose of the study:

The purpose of this study is to see if the study drug, lenalidomide, will improve thinking and memory skills and reduce inflammation in the brain. The study will also assess the safety and tolerability of its use in patients with mild cognitive impairment.

To qualify for this study you must:

- Be at least 50 years of age
- Have a diagnosis of mild cognitive impairment due to Alzheimer's disease
- Be able to have diagnostic tests performed such as MRI, PET/CT
- Have a study partner who has at least 10 hours a week of direct contact with you

The study doctor will check for other medical conditions or reasons that would prevent you from participating in the study.

If you are interested in participating or would like additional information, please contact us:

702.701.7944